Crossref
A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis
Brain · 17.10.2026
DOI: 10.1093/brain/awag360 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, online erschienen am 17.10.2026. Verfasst von Sean A Freeman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Toulouse University Hospitals, Toulouse, France. Die Arbeit nennt 9 Literaturangaben. Gefördert von: France-SEP, French MS society, Sobek Foundation.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Neurology, Toulouse University Hospitals, Toulouse, France.
- University of Toulouse, INSERM, CNRS, Infinity - Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
- Department of Immunology, Toulouse University Hospitals, Toulouse, France.
ORCID-Profile: Roland S Liblau
Förderung
- France-SEP
- French MS society
- Sobek Foundation
Zitieren
APA
Freeman, S. A., & Liblau, R. S. (2026). A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis. Brain. https://doi.org/10.1093/brain/awag360
Vancouver
Freeman SA, Liblau RS. A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis. Brain. 2026. doi:10.1093/brain/awag360
BibTeX
@article{Freeman2026,
author = {Freeman, Sean A and Liblau, Roland S},
title = {A novel TARGET for anti-CD20 antibody therapy in multiple sclerosis},
journal = {Brain},
year = {2026},
doi = {10.1093/brain/awag360}
}
EUVIMED